On May 5, 2025, President Donald Trump signed an executive order focused on increasing domestic production of prescription drugs and reducing reliance on foreign pharmaceutical sources.
• The order instructs the Food and Drug Administration (FDA) to simplify the approval process for new drug manufacturing facilities by removing unnecessary regulations and speeding up reviews.
• A key element is to reduce obstacles in the Environmental Protection Agency (EPA)’s permitting process.
• Trump highlighted the order's importance and hinted at a significant announcement regarding pharmaceuticals the following week.
• The EPA is directed to expedite the construction of facilities for producing prescription drugs, active pharmaceutical ingredients (APIs), and essential materials, aiming to lessen the time needed to build new plants.
• The order also mandates increased inspections and higher fees for foreign drug manufacturers to promote domestic production.
• The White House acknowledges existing challenges in creating reliable and affordable pharmaceutical supply chains in the U. S.
• Potential timeframes for building new pharmaceutical manufacturing capacity could take between five to ten years, which is viewed as a significant national security issue.
• The administration has launched a Section 232 investigation to assess the national security impact of pharmaceutical imports, which may result in tariffs on foreign medicines.
• The U. S. currently relies heavily on global production for generic drugs, with a considerable percentage of ingredients sourced from China, which poses risks to the U. S. healthcare system.
• The government is gathering input from various stakeholders, including industry experts, to inform potential tariffs on pharmaceuticals and semiconductors.
The executive order marks a substantial effort to enhance U. S. pharmaceutical manufacturing capabilities and ensure national security by addressing the over-dependence on foreign sources, particularly from China.
No comments:
Post a Comment